லிநில News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from லிநில. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In லிநில Today - Breaking & Trending Today

Researchers Develop Precision Scale for Extremely High-Pressure Experiments


Scientists from Lawrence Livermore National Laboratory (LLNL), Sandia National Laboratories (SNL), and the University of Hyogo in Kobe, Japan, have developed a way to more precisely measure high-pressure compression in the laboratory up to 10 million atmospheres.
LLNL said pressures exceeding 1 million atmospheres can alter how atoms are packed together, which can lead to new chemical bonding. Testing the quantum theory of condensed matter under enormous pressure has produced such discoveries as helium rain, a transparent sodium metal, superionic water ice, and the transformation of hydrogen into a metallic fluid.
But, until now, most extremely high-pressure experiments – as much as 1 terapascal, or approximately 10 million atmospheres – relied on theoretical models or extrapolation of low-pressure measurements to determine just how much pressure was being applied. ....

New Mexico , United States , Dayne Fratanduono , Lawrence Livermore National Laboratory , National Ignition Facility , Sandia National Laboratories , University Of Hyogo , Sandiaz Machine , Lawrence Livermore National Library , Sandia National Laboratory , Igh Pressure Compression , Dayne Fratanduono , Quantum Chemistry , புதியது மெக்ஸிகோ , ஒன்றுபட்டது மாநிலங்களில் , லாரன்ஸ் லிவர்மோர் தேசிய ஆய்வகம் , தேசிய பற்றவைப்பு வசதி , சாண்டியா தேசிய ஆய்வகங்கள் , பல்கலைக்கழகம் ஆஃப் ஹியோகோ ,

Silence Therapeutics gets £2m milestone payment from Mallinckrodt partnership | 28 April 2021


28 April 2021 | 09:20am
StockMarketWire.com - RNA-based therapy developer Silence Therapeutics said it had achieved another research milestone as part of an ongoing collaboration with Mallinckrodt for complement-mediated diseases.
Reaching the milestone had triggeed a further $2.0 million payment to Silence.
The milestone related to pre-clinical development work on the SLN500 C3 targeting program.
Silence said it continued to work with Mallinckrodt to progress investigational new drug enabling studies for SLN501, the first nominated product candidate in the SLN500 program, this year.
At 9:20am: [LON:SLN] Silence Therapeutics PLC share price was 0p at 455p
Story provided by StockMarketWire.com
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. ....

Silence Therapeutics , Silence Therapeutics Plc , Lon Sln , ம .னம் சிகிச்சை , ம .னம் சிகிச்சை ப்ல் ,